CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

We recently compiled a list of the Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires. In this article, ...

Moderna lost more than 20% of its value on the ... stressing savings as key to its goal of balancing cash flow by 2028. Ahead of CEO Stéphane Bancel’s address at the JP Morgan Healthcare ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Drug maker Moderna 's stock plunged more than 17% in pre-market trading on Monday after the company slashed its sales outlook ...

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Earlier this month, Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s lackluster vaccine sales in COVID-19 and respiratory syncyti ...

MODERNA cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Moderna CEO Stephane Bancel said full-year cash operating expenses for 2024 fell 25% year-over-year. "We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 ...

Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...